Research programme: hepatitis C therapeutics - EnantaAlternative Names: EP-CyP212; EP-NS5A25; HCV cyclophilin binders - Enanta; HCV NS5A protein inhibitors - Enanta/Novartis; HCV polymerase inhibitors - Enanta; Tetrazole type hepatitis C serine protease inhibitors - Enanta
Latest Information Update: 11 Feb 2015
At a glance
- Originator Enanta Pharmaceuticals
- Class Small molecules; Tetrazoles
- Mechanism of Action Cyclophilin inhibitors; Hepatitis C protease inhibitors; Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatitis C